Table 4. Relationship between the first and last ALT readings and the demographic and clinical characteristics of the patients (N = 88).

ALT: alanine aminotransferase

p-values were calculated using the Fisher exact test

** Significant at p < 0.05 level

Factor	Pre-treatment ALT readings		p-value	Last ALT readings		p-value
	Normal, n (%) (n = 95)	High, n (%) (n = 02)		Normal. n (%) (n = 92)	High, n (%) (n = 4)
Age group
≤22 years	49 (51.6%)	2 (100%)	0.496	47 (50.5%)	4 (100%)	0.119
>22 years	46 (48.4%)	0 (0%)		46 (49.5%)	0 (0%)
Gender
Male	28 (29.5%)	2 (100%)	0.093	26 (28.0%)	4 (100%)	0.008 **
Female	67 (70.5%)	0 (0%)		67 (72.0%)	0 (0%)
Age of acne onset
11–15 years	19 (20.0%)	0 (0%)	1.000	18 (19.4%)	1 (25.0%)	0.526
16–19 years	30 (31.6%)	1 (50.0%)		29 (31.2%)	2 (50.0%)
>19 years	46 (48.4%)	1 (50.0%)		46 (49.5%)	1 (25.0%)
Age at which isotretinoin treatment began
≤20 years	48 (50.5%)	0 (0%)	0.253	46 (49.5%)	2 (50.0%)	1.000
21–23 years	33 (34.7%)	2 (100%)		33 (35.5%)	2 (50.0%)
>23 years	14 (14.7%)	0 (0%)		14 (15.1%)	0 (0%)
Starting dose
10–20 mg	83 (87.4%)	2 (100%)	1.000	81 (87.1%)	4 (100%)	1.000
30–40 mg	12 (12.6%)	0 (0%)		12 (12.9%)	0 (0%)
Ending dose
10–20 mg	41 (43.2%)	2 (100%)	0.295	40 (43.0%)	3 (75.0%)	0.465
30–40 mg	49 (51.6%)	0 (0%)		48 (51.6%)	1 (25.0%)
>40 mg	5 (5.3%)	0 (0%)		5 (5.4%)	0 (0%)
Duration of treatment
<5 months	58 (61.1%)	2 (100%)	0.523	57 (61.3%)	3 (75.0%)	1.000
≥5 months	37 (38.9%)	0 (0%)		36 (38.7%)	1 (25.0%)
Previous isotretinoin use
Yes	7 (7.4%)	0 (0%)	1.000	6 (6.5%)	1 (25.0%)	0.263
No	88 (92.6%)	2 (100%)		87 (93.5%)	3 (75.0%)
Weight
30–50 kg	17 (20.7%)	0 (0%)	0.494	16 (20.0%)	1 (33.3%)	0.116
51–70 kg	42 (51.2%)	0 (0%)		42 (52.5%)	0 (0%)
>70 kg	23 (28.0%)	1 (100%)		22 (27.5%)	2 (66.7%)